Protalix BioTherapeutics Inc (AMEX: PLX) on Monday, soared 8.71% from the previous trading day, before settling in for the closing price of $2.41. Within the past 52 weeks, PLX’s price has moved between $0.82 and $2.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3.84%. The company achieved an average annual earnings per share of 675.00%. With a float of $72.17 million, this company’s outstanding shares have now reached $75.85 million.
Let’s determine the extent of company efficiency that accounts for 213 employees. In terms of profitability, gross margin is 54.46%, operating margin of 7.34%, and the pretax margin is 7.78%.
Protalix BioTherapeutics Inc (PLX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Protalix BioTherapeutics Inc is 7.51%, while institutional ownership is 6.63%.
Protalix BioTherapeutics Inc (PLX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 675.00% per share during the next fiscal year.
Protalix BioTherapeutics Inc (AMEX: PLX) Trading Performance Indicators
Protalix BioTherapeutics Inc (PLX) is currently performing well based on its current performance indicators. A quick ratio of 1.52 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.83. Likewise, its price to free cash flow for the trailing twelve months is 27.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.03, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Protalix BioTherapeutics Inc (PLX)
Looking closely at Protalix BioTherapeutics Inc (AMEX: PLX), its last 5-days average volume was 0.81 million, which is a jump from its year-to-date volume of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 63.07%. Additionally, its Average True Range was 0.16.
During the past 100 days, Protalix BioTherapeutics Inc’s (PLX) raw stochastic average was set at 89.71%, which indicates a significant decrease from 97.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.31% in the past 14 days, which was higher than the 57.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.44, while its 200-day Moving Average is $1.64. However, in the short run, Protalix BioTherapeutics Inc’s stock first resistance to watch stands at $2.69. Second resistance stands at $2.77. The third major resistance level sits at $2.90. If the price goes on to break the first support level at $2.48, it is likely to go to the next support level at $2.35. Should the price break the second support level, the third support level stands at $2.27.
Protalix BioTherapeutics Inc (AMEX: PLX) Key Stats
Market capitalization of the company is 204.44 million based on 78,033K outstanding shares. Right now, sales total 53,400 K and income totals 2,930 K. The company made 18,220 K in profit during its latest quarter, and 6,490 K in sales during its previous quarter.
